Topics:

Oncology and Hematology News and Journal Articles

National Lung Screening Trial Limitations and Public Health Policy

NLST data clearly demonstrate that lung cancer screening is effective and safe and reduces lung cancer-specific mortality by at least 20%. There is no possible reason for CMS to further delay or restrict lung cancer screening for those at high risk.

Recent Content

According to a report, two courses of the newly approved agent blinatumomab, for relapsed or refractory B-cell precursor ALL, will cost a staggering $178,000.

This slide show features some of the top highlights from the 2014 San Antonio Breast Cancer Symposium, including ovarian suppression in ER-positive breast tumors, tamoxifen for disease prevention, and immunotherapies for triple-negative breast cancer.

Researchers have identified several factors, including breastfeeding and oral contraceptives, that may decrease the risk of BRCA-associated ovarian cancer.

Long-term survival rates of patients after laparoscopic surgery for bladder cancer are similar to rates achieved with standard open surgery.

The US Food and Drug Administration approved lanreotide for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

Researchers have identified two new panRAF inhibitors that could be used to treat patients with BRAF- or NRAS-mutant melanoma, and those who have developed resistance to BRAF inhibitors.

An analysis showed that etoposide-cisplatin or carboplatin-paclitaxel with RT yielded similar survival in patients with stage III non-small-cell lung cancer.

By clicking Accept, you agree to become a member of the UBM Medica Community.